welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis
source: Clinical cancer research
year: 2000
authors: van Stolk R, Stoner G, Hayton W L, Chan K, DeYoung B, Kresty L, Kemmenoe B H, Elson P, Rybicki L, Church J, Provencher K, McLain D, Hawk E, Fryer B, Kelloff G, Ganapathi R, Budd G T
summary/abstract:Exisulind (sulindac sulfone; FGN-1), a metabolite of sulindac without known effects on prostaglandin synthesis, can promote apoptosis and inhibit tumorigenesis in preclinical systems. We performed a Phase I trial of this compound in patients with familial adenomatous polyposis (FAP) to examine the tolerability and safety of this drug in the cancer chemoprevention setting. Six patients each were treated with exisulind at doses of 200, 300, and 400 mg p.o. twice a day. Reversible hepatic dysfunction was noted in four of six patients treated at the 400-mg p.o., twice-a-day dose level, but in only one to two of six patients treated at each of the lower dose levels. The serum half-life of exisulind was 6-9 h; little drug accumulation was noted over time. A nonsignificant trend toward increased apoptosis in polyps was noted at the maximum tolerated dose, but no decrease in polyp numbers or significant effects on cellular proliferation was noted. After treatment, polyps tended to display a “halo” appearance grossly and mucinous differentiation histologically. The maximum safe dose of exisulind is 300 mg p.o. twice a day in patients with subtotal colectomies. Reversible hepatic dysfunction limits further dose escalation. A decrease in polyp numbers could not be demonstrated, but the trend toward increased apoptosis at the MTD and the observation of mucinous change histologically suggest that further investigation of drugs of this class might be warranted.
organization: Cleveland Clinicread more full text source
expertly curated content related to this topic
-
Laparoscopic Restorative Proctocolectomy: Case-Matched Comparative Study with Open Restorative ProctocolectomyPURPOSE : A laparoscopic approach to res...
-
Rectal Eversion and Double-Stapled Ileal Pouch Anal Anastomosis in Familial Adenomatous Polyposis SyndromeINTRODUCTION : Surgery is the only treat...
-
Prevalence and Outcome of Anemia After Restorative Proctocolectomy: A Clinical Literature ReviewPURPOSE : Iron and/or vitamin B12 defici...
-
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal SurgeryThis will be a prospective, multi-center...
-
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors̵...Colorectal cancer (CRC) is a leading cau...
-
Polyposis Syndromes of the Colon Current Management, Controversies and Future Directionhttp://www.slideserve.com/verena/polypos...
-
Tucson drug startup launches gastric-cancer trialTucson-based drug startup Cancer...